When nanotechnology is used in medicine, it makes it easier to find and treat a wide range of diseases. One of the oral options for treating multiple sclerosis (MS) is dimethyl fumarate (DMF). DMF has been shown to be effective in lowering inflammatory diseases; nevertheless, it is characterized by several undesirable side effects that reduce patient compliance and add financial obstacles. The aim of this study was to use platelet membranes and platelet nanoparticles to generate a drug delivery system that works like a cell, so as to treat MS. During the experiments, there is a chance that the DMF solution might harden at room temperature. Therefore, in order to produce solid lipid nanoparticles (SLNs), DMF was combined with biocompatible lipids. The creation of SLNs involved the use of hot emulsion and ultrasonication. These DMF-SLNs were characterized by means of scanning electron microscopy, and Fourier-transform infrared spectroscopy. The herein demonstrated enhanced qualities of the devised SLNs suggest that the formulation may be a potential, longer-acting formulation for the improved management of MS. SLNs could change the way many illnesses are treated in a big way, if they are used for the delivery of medicines.